Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

Prenatal Hyperlipidemia: ‘Canary in a Coal Mine’ for Maternal Health?

L.A. McKeown

October 17, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

News Conference News ACC 2024

Faster CAC Progression After Menopause May Warrant Intensified Therapy

L.A. McKeown

April 04, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Daily News

AI Tool Can Quantify CAC—and Associated CV Risk—From PET

Yael L. Maxwell

September 14, 2022

News Daily News

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Michael O'Riordan

September 23, 2021

News Daily News

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

Alexandra Dangas

September 06, 2021

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

News Daily News

Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds

Michael O'Riordan

February 06, 2020

News Daily News

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Yael L. Maxwell

January 10, 2019

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Daily News

Statins Seem to Reduce Alzheimer’s Disease Risk, But Race/Ethnicity and Statin Type Matter

Todd Neale

December 14, 2016

News Daily News

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

Michael O'Riordan

November 13, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

Advertisement

Prenatal Hyperlipidemia: ‘Canary in a Coal Mine’ for Maternal Health?

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Faster CAC Progression After Menopause May Warrant Intensified Therapy

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

AI Tool Can Quantify CAC—and Associated CV Risk—From PET

Cumulative Burden of LDL Cholesterol Increases CHD Risk

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Evolocumab Not Cost-Effective at Current List Price

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Statins Seem to Reduce Alzheimer’s Disease Risk, But Race/Ethnicity and Statin Type Matter

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content